Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India

Oncology

Volumn 77, Issue 3-4, 2009, Pages 162-171

  Paul, Shashi B ^b   Chalamalasetty, Sreenivasa Baba ^a   Vishnubhatla, Sreenivas ^b   Madan, Kaushal ^a   Gamanagatti, Shivanand R ^b   Batra, Yogesh ^a   Gupta, Siddhartha D ^a   Panda, Subrat K ^a   Acharya, Subrat K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Radiodiagnosis ^*  (India)

Author keywords

Etiology; Hepatocellular carcinoma; India; Serum fetoprotein; Staging; Treatment

Indexed keywords

ANTIINFECTIVE AGENT; RHENIUM;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; INDIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; FEMALE; HEPATITIS B; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 67651221808     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000231886     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, et al: Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001; 94: 153-156. (Pubitemid 32911406)
2. Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285.
3. Pisani P, Parkin DM, Ferlay J: Estimates of the world wide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-893.
4. Bruix J, Sherman M, Llovet JM, et al: EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona 2000 EASL conference. European Association for the Study of Liver. J Hepatol 2001; 35: 421-430.
5. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62(suppl 1):8-17.
6. Acharya SK, Madan K, Datta Gupta S, Panga SK: Viral hepatitis in India. Natl Med J India 2006; 19: 203-217.
7. Kumar M, Kumar R, Hissar SS, et al: Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol 2007; 22: 1104-1111.
8. Chowdhury A, Santra A, Chaudhuri S, et al: Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 2003; 37: 802-809.
9. Prabhakar V, Rao KS, Reddy DJ: Primary carcinoma of liver in Visakhapatnam. Indian J Pathol Microbiol 1966; 9: 54-60.
10. Paul SB, Sreenivas V, Gulati MS, et al: Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India. Indian J Gastroenterol 2007; 26: 274-278.
11. Kumar Acharya S, Kumar Sharma P, Singh R, et al: Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007; 46: 387-394.
12. Panigrahi AK, Panda SK, Dixit RK, et al: Magnitude of hepatitis C virus infection in India: prevalence in healthy blood donors, acute and chronic liver diseases. J Med Virol 1997; 51: 167-174.
13. Panigrahi AK, Roca J, Acharya SK, Jameel S, Panda SK: Genotype determination of hepatitis C virus from northern India: identification of a new subtype. J Med Virol 1996; 48: 191-198.
14. Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK: Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004; 127: 1356-1371.
15. Hazari S, Acharya SK, Panda SK: Development and evaluation of a quantitative competitive reverse transcription polymerase chain reaction (RT-PCR) for hepatitis C virus RNA in serum using transcribed thio- RNA as internal control. J Virol Methods 2004; 116: 45-54.
16. Pugh RN, Murray M, Dawson MC, et al: Transection of esophagus for bleeding esophageal varices. Br J Surg 1973; 60: 646-648.
17. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liv Dis 1999; 19: 329-338.
18. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK: Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002; 17: 165-170.
19. Tanaka Y, Hasegawa I, Kato T, et al: A case control study for difference among hepatitis B virus infections of genotype A (subtype Aa and Ae) and D. Hepatology 2004; 40: 747-755.
20. Sarin SK, Thakur V, Guptan RK, et al: Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations. J Gastroenterol Hepatol 2001; 16: 666-673.
21. Murugavel KG, Mohan KVK, Pramod NP, et al: Correlation of hepatitis B and C viral markers with aflatoxin and AFP in hepatocellular carcinoma cases from Tamil Nadu. Abstract. Indian J Gastroenterol 1999; 18: S37.
22. Kapoor S, Gupta SK, Dhiman RK, et al: Hepatocellular carcinoma at PGI Chandigarh. Indian J Gastroenterol 1999; 18:S36.24.
23. Tandon BN, Acharya SK, Tandon A: Epidemiology of hepatitis B virus infection in India. Gut 1996; 38: 856-859.
24. Ramesh R, Munshi A, Panda SK: Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatocellular carcinoma patients in India. J Gastroenterol Hepatol 1992; 7: 393-395.
25. Panigrahi AK, Panda SK, Dixit RK, et al: Magnitude of hepatitis C virus infection in India: prevalence in healthy donors, acute and chronic liver disease. J Med Virol 1997; 51: 167-174.
26. Stroffolini T, Andreone P, Andriulli A, et al: Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998; 29: 944-952.
27. Shiratori Y, Shiina S, Imamura M, et al: Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22: 1027-1033.
28. Tandon BN, Irshad M, Raju M, Mathur GP, Rao MN: Prevalence of HbsAg and anti- HBC in children and strategy suggested for immunization in India. Indian J Med Res 1991; 93: 337-339.
29. Sobeslavsky O: Prevalence of markers of hepatitis B virus infection in various countries: a WHO collaborative study. Bull WHO 1980; 58: 621-628.
30. Aggarwal R, Naik SR: Prevention of hepatitis B infection: the appropriate strategy for India. Natl Med J India 1994; 7: 216-220.
31. International Agency for Research on Cancer: Monographs on the Evolution of Carcinogenic Risks to Humans: Hepatitis Viruses, vol 59. Geneva, World Health Organisation, 1994.
32. Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK: Characteristics of HCC in India. QJM 2008; 101: 479-485.
33. Paul SB, Gulati MS, Sreenivas V, et al: Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007; 72(suppl 1):117-123.
34. Fattovich G, Stroffoloni T, Zagni I, et al: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127:S35-S50.
35. Daniele B, Bencivenga A, Megna AS, Tinessa V: Alpha fetoprotein and ultrasonography screening for hepatocelluar carcinoma. Gastroenterology 2004; 127:S108-S112.
36. Watanabe A, Yamamoto H, Ito T, et al: Diagnosis, treatment and prognosis of small hepatocellular carcinoma. Hepatogastroenterlogy 1986; 33: 52.
37. Sangro B, Herraiz M, Martinez-Gonzalez MA, et al: Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery 1998; 124: 575-583. Erratum in: Surgery 1998; 124: 1087.
38. Schoniger-Hekele M, Muller C, Kutilek M, et al: Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol 2000; 12: 941-948.
39. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156.
40. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
41. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
42. Takayasu K, Arii S, Ikai I, et al; Liver Cancer Study Group of Japan: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 2006; 131: 461-469.
43. Liu YM, Qin H, Wang CB, Fang XH, Ma QY: Comparison of therapeutic effectiveness of combined interventional therapy for 1,126 cases of primary liver cancer. World J Gastroenterol 2006; 12: 5060-5063.
44. Wang TE, Kao CR, Lin SC, et al: Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10: 649-653.
45. Lin AY, Brophy N, Fisher GA, et al: Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103: 119-125.
46. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.